Business
Completion of Acquisition
Completion of Acquisition.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n Hikma Pharmaceuticals Plc\n26 January 2007\n\n\n\n Hikma completes its acquisition of Ribosepharm\n\nLONDON, 26 January 2007 - Following the announcement made by Hikma\nPharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX: HIK), the multinational\npharmaceuticals group, on 22 January 2007 regarding the acquisition of\nRibosepharm GmbH, Hikma today announces that the transaction has been completed.\n\nSamih Darwazah, Chairman & CEO of Hikma, commented: 'The acquisition of\nRibosepharm provides us with an excellent platform from which to enter the large\nand fast-growing oncology market, which is forecast to become the second largest\nwithin the pharmaceutical industry by 2010. Ribosepharm has a strong position in\nGermany, one of the largest European oncology markets, and significant\ndistribution capabilities. We will be able to draw on its experience in the\nfield of oncology and use its expertise to expand into other oncology markets in\nEurope, as well as into the United States and the MENA region. We look forward\nto working with Dr. Kudielka, Ribosepharm's Managing Director, and his\nexperienced team.'\n\n - ENDS -\nEnquiries:\n\nHikma Pharmaceuticals PLC\n\nSusan Ringdal, Investor Relations Director +44 20 7399 2760\n\nBrunswick Group\n\nJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959\n\nAbout Hikma\n\nHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on\ndeveloping, manufacturing and marketing a broad range of both branded and\nnon-branded generic and in-licensed pharmaceutical products. Hikma's operations\nare conducted through three businesses: Generic, Branded and Injectable\nPharmaceuticals. Hikma's operations are based principally in the United States,\nthe Middle East and North Africa ('MENA') region and Europe. In 2005, the Group\nhad revenue of $262 million and profit attributable to shareholders of $44\nmillion. At 31 December 2005, the Group had over 1,800 employees. For news and\nother information, please visit www.hikma.com.\n\nAbout Ribosepharm\n\nRibosepharm is a well-established and successful oncology company, specialising\nin the marketing and distribution of branded generic injectable oncology\nproducts both to private practices and hospitals in Germany.\n\n\n\n This information is provided by RNS\n The company news service from the London Stock Exchange\n \n ","length"...